| Aurora Biosciences Corporation | |||
| Ticker: | ABSC | 11149 North Torrey Pines Road | |
| Exchange: | NASDAQ-National Market | La Jolla, CA 92037 | |
| Industry: | Service (SIC Code 8731) | (619) 452-5000 | |
| Type of Shares: | Common Shares | Filing Date: | 3/14/97 | |
| U.S. Shares: | 4,000,000 | Offer Date: | 6/19/97 | |
| Non-U.S. Shares: | 0 | Filing Range: | $9.00 - $11.00 | |
| Primary Shares: | 4,000,000 | Offer Price: | $10.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.70 | |
| Offering Amount: | $40,000,000 | Selling: | $0.40 | |
| Expenses: | $600,000 | Reallowance: | $0.10 | |
| Shares Out After: | 15,893,814 |
| Manager | Tier | Phone |
| Alex. Brown & Sons Incorporated | Lead Manager | (410) 895-2700 |
| Hambrecht & Quist Incorporated | Co-manager | (415) 439-3626 |
| Robertson, Stephens & Company | Co-manager | (415) 989-8500 |
| Issuer's Law Firm: | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm: | Morrison & Foerster |
| Auditor: | Ernst & Young |
| Registrar/Transfer Agent: | Harris Trust Company of California |
Dollar amounts in U.S. millions except for per share data | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/96 | 12/31/96 | ||||
| Revenue: | $2.22 | Assets: | $17.52 | ||
| Net Income: | -$2.93 | Curr Assets: | |||
| EPS: | -$0.26 | Liabilities: | $2.33 | ||
| Prior EPS: | -$0.14 | Curr Liabilities: | |||
| Cash Flow/Oper: | -$3.52 | Equity: | $15.18 | ||
| Cash Flow/Fin: | Cash: | ||||
| Cash Flow/Inv: | |||||
| Business Description |
| The company designs and develops proprietary drug discovery systems, services and technologies to accelerate and enhance the discovery of new medicines. The company is developing and integrated technology platform comprised of a portfolio of proprietary fluorescent technology platform comprised of a portfolio of proprietary fluorescent assay technologies and an ultra-high throughout screening system designed to allow assay miniaturization and to overcome many of the limitations associated with the traditional drug discovery process. The company believes that this platform will enable the company and its collaborators, which include Bristol-Myers Squibb and Eli Lilly and Company, to take advantage of the opportunities created by recent advances in geonomics and combinatorial chemistry that have generated many new therapeutic targets and an abundance of new small molecule compounds. The company believes its integrated platform will accelerate the drug discovery process by shortening the time required to identify high quality lead compounds and to optimize those compounds into drug development candidates. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for working capital and general corporate purposes including facilities expansion and improvements, capital equipment purchases, enhancement of internal research and development and the acquisition of chemical libraries.. |